Bicycle Therapeutics PLC expected to post a loss of $1.24 a share - Earnings Preview

Bicycle Therapeutics

30/04/2024 15:16

* Bicycle Therapeutics PLC  BCYC.OQ   BCYC.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 2
(estimated) for the period ending March 31 2024
    * The Cambridge Cambridgeshire-based  company is expected to
report a 23.2% increase in revenue to $6.029 million from $4.9
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Bicycle Therapeutics PLC
is
for a loss of $1.24 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Bicycle
Therapeutics PLC is $41.50​, above​ its last closing price
of $23.41. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -1.17       -1.23      -1.16     Beat    6
 Sep. 30 2023  -1.16       -1.17      -1.26     Missed  -7.6
 Jun. 30 2023  -1.31       -1.29      -1.41     Missed  -9​
 Mar. 31 2023  -1.08       -1.07      -1.30     Missed  -21.1
 ​​Dec.        -1.05       -1.06      -1.01     Beat    4.6
 31 2022                                                
 Sep. 30 2022  -0.86       -0.89      -0.96     Missed  -8​
 Jun. 30 2022  -0.89       -0.85      -0.90     Missed  -6.1
 Mar. 31 2022  -0.70       -0.68      -0.93     Missed  -36.4
 This summary was machine generated April 30 at 14:15 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)